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Nasal specific IgE correlates to serum specific IgE: First steps 
towards nasal molecular allergy diagnostic
To the Editor,
Up to 40% of the European population suffer from respiratory 
type I hypersensitivity reactions induced by airborne allergens, such 
as plant pollen, fungal spores, or dust mite feces.1 Guidelines for the 
treatment of AR in children recommend causative treatment, that 
is, allergen-specific immunotherapy (ASIT), as early as possible.2 
Allergy diagnostics is routinely performed by skin prick test (SPT) 
or blood test for the detection of allergen-specific immunoglobulin 
E (sIgE). If specific serum IgE is absent despite a positive history of 
allergic rhinitis, a nasal allergen provocation test is performed to 
assess local allergic rhinitis (LAR). Recent developments in micro-
chip technology enabled the simultaneous detection of specific IgE 
levels against 112 individual allergens using only 30 µL of serum. 
However, SPTs are still often the method of choice when diagnos-
ing young children, as children are typically afraid of needles. This 
can lead to improper diagnosis, since SPTs are prone to false-pos-
itive results due to the unspecified extracts used.3 The aim of our 
study was therefore to adopt the Immuno Solid-phase Allergen 
Chip (ISAC) for nasal fluid as a noninvasive sampling method and to 
validate the technology as potential novel allergy test. Our analysis 
(see details in online supporting information) focused on the most 
relevant aeroallergens, that is, house dust mite (HDM), Betulaceae 
trees, including birch, hazel and alder, and grass pollen.4
Blood and nasal fluid samples as previously described 5 were ob-
tained from 2 nonsensitized (NS) control subjects and 47 subjects 
sensitized (Figure S1and Table S2. online supporting information) to 
aeroallergens such as birch, hazel, alder, grass pollen, or house dust 
mite (HDM). Specific IgE levels were measured in sera and nasal fluid 
by the ImmunoCAP ISAC 112 (Table S1. online supporting informa-
tion) according to the manufacturer's instruction (Thermo Fischer 
Scientific).
When correlating IgE against single allergen components, we ob-
served a significant positive correlation (n = 49; P < .001) between 
serum and nasal tests (Figure 1, A), with a median of all Spearman 
correlation coefficients (rs) across the whole panel of 0.77 (IQR 0.75, 
0.85). The highest correlation coefficient was observed for Der p 
2 and Aln g 1 (rs = .88), followed by Cor a 1 (rs = .87) and Bet v 1 
(rs = .85) (Figure 1, B).
We next determined the global sensitization profile of each 
subject's serum and nasal fluid and compared the profiles for all 
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F I G U R E  1   Correlation between nasal and serum sIgE levels. A, Spearman correlation coefficients for all tested allergen components. 
B, Nasal sIgE levels (y-axis) plotted against serum sIgE levels (x-axis). Dots indicate study subjects. Fitted lines indicate positive linear 
correlations (Spearman). C, Spearman correlation coefficients per subject over the entire aeroallergen sensitization profile, as shown in panel 
A. D, Serum sIgE profile (x-axis) versus nasal sIgE profile (y-axis) shown for selected subjects. Blue dots indicate the 17 allergen-specific IgE 
tests included in the overall analysis. The red line represents the linear regression curve fit (positive Spearman correlation)
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subjects (Figure 1, C). We observed a strong positive correlation 
between serum and nasal sIgE profiles, and the median Spearman 
correlation coefficient was rs = .75, the IQR 0.68, 0.88. The only 
poor correlations observed were for subjects No 01, 08, 16, 26, and 
46. The highest correlations were observed for subjects with sev-
eral sensitizations, whereas nonsensitized subjects showed poorer 
correlations (see Figure 1, D for overview over selected subjects).
Finally, we evaluated the performance of the ISAC tests in serum 
and nasal fluid in comparison with the ImmunoCAP method by as-
sessing cutoff, sensitivity, specificity, likelihood ratios, and operating 
characteristics. First, a nasal fluid cutoff threshold was estimated by a 
receiver operating characteristics (ROC) curve using Youden's index. 
The area under the curve (AUC) for nasal fluid (0.93) and serum tests 
(0.97) was found to be comparable (Figure 2, A). The nasal threshold 
was calculated to be 0.08 ISU-E. The diagnostic capability of sIgE 
determination for birch pollen (Bet v 1, Bet v 2, and Bet v 4), grass 
pollen (Cyn d 1, Phl p 1, Phl p 2, Phl p 5, and Phl p 6), and HDM (Der f 
1, Der f 2, Der p 1, and Der p 2) was assessed by a two-by-two table 
(Figure 2, B). Specificity (serum: 0.95 and, nasal: 0.96) and positive 
prediction value (serum: 0.96 and nasal: 0.97) were similar for both 
methods. The diagnostic sensitivity and negative prediction value of 
serum diagnostic were higher than nasal diagnostic (TPR serum: 0.94 
vs TPR nasal: 0.85; NPV serum: 0.92 vs NPV nasal: 0.82). In addition, 
diagnostic accuracy was determined by calculating likelihood ratios 
for serum (LR+ 17.83, LR− 0.07) and nasal biosampling (LR+ 24.28, 
LR− 0.15). Further statistical analyses were done to complement the 
results (Figure 2, C).
We demonstrate similar specificities of ISAC for serum and 
nasal fluid tests, whereas the sensitivity in the serum test is higher 
than in the nasal test. A likely explanation for the lower sensitiv-
ity in our nasal tests is that the manufacturer's instructions are 
optimized for the serum matrix. Consequently, the experimental 
setup (eg, incubation times, fluorescent marker, sampling methods) 
should be improved further to raise sensitivity of nasal fluid diag-
nostic. Moreover, the threshold for the nasal fluid test, as assessed 
in the current study, could be set to an even lower value (0.08) than 
recommended for serum by the manufacturer (0.3) without losing 
specificity. Overall, sIgE levels against all tested allergen compo-
nents were significantly and positively correlated between nasal 
fluid and serum, and the inter-sample correlation was best for sIgE 
against birch and grass pollen and HDM (Figure S2. online support-
ing information). Recent studies comparing ISAC tests in serum and 
nasal fluid have shown similar results6-9; however, these studies 
compared only tests for single allergens, that is, house dust mite, 
Japanese cedar, mugwort pollen, and fungal spores, instead of a 
whole aeroallergen panel.
To conclude, we present the first study to assess whole pat-
terns of IgE specific to aeroallergens in serum and nasal fluid and to 
systematically evaluate the novel, ISAC-based method in compari-
son with clinical standard diagnostics. Our results could be of high 
F I G U R E  2   Receiver operating characteristic (ROC) curve for nasal and serum IgE test, and their comparison of ImmunoCAP and ISAC 
diagnostic. A, The ROC curves are generated by plotting nasal (blue) and serum (red) data. “J” indicates the threshold for positive nasal test. 
B, Contingency table for tests in serum and nasal fluid. C, Statistical analysis to verify performance of serum and nasal ISAC. Diagnostics via 
ImmunoCAP served as control
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relevance for the future improvement of clinical diagnostics, espe-
cially in children with allergic airway disease.
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Cadherin-related family member 3 upregulates the effector 
functions of eosinophils
To the Editor,
Acute respiratory infections including rhinovirus (RV) infections are 
a major cause of asthma exacerbations.1 Recent studies suggest that 
eosinophils play important roles in the development of asthma exac-
erbation.2 Not only neutrophils but also eosinophils increase in asth-
matic airways during viral infection,3 suggesting that eosinophils are 
indeed recruited to and activated in the airways during virus-related 
asthma exacerbations.
Cadherin-related family member 3 (CDHR3), a member of the 
cadherin superfamily, is a transmembrane protein with six extra-
cellular cadherin domains. However, the biological function of 
CDHR3 is still unknown. Recently, Bønnelykke et al4 reported that 
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